Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.41 |
| ▸ | FAP | Q12884 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 2/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.34 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | NECTIN4 | Q96NY8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25833839 | 0.88 | CYP3A4 (0.41) | CYP3A4FOLH1FAPTTRSIRT2 | |
| SCHEMBL26223056 | 0.88 | CYP3A4 (0.38) | CYP3A4FOLH1FAPSIRT2SIRT1 | |
| SCHEMBL25858562 | 0.87 | CYP3A4 (0.42) | CYP3A4FOLH1FAPTTR | |
| SCHEMBL20095233 | 0.86 | FOLH1 (0.40) | CYP3A4FOLH1FAPTTRSIRT2 | |
| SCHEMBL19869062 | 0.86 | FOLH1 (0.40) | CYP3A4FOLH1FAPTTRSIRT2 | |
| SCHEMBL20385923 | 0.85 | CYP3A4 (0.46) | CYP3A4FOLH1FAPTTRNECTIN4 | |
| SCHEMBL20095333 | 0.85 | CYP3A4 (0.37) | CYP3A4FOLH1FAPTTRL3MBTL1 | |
| SCHEMBL22241542 | 0.85 | CYP3A4 (0.37) | CYP3A4FOLH1FAPTTRL3MBTL1 | |
| SCHEMBL25829056 | 0.84 | CYP3A4 (0.40) | CYP3A4FOLH1FAPTTRSIRT2 | |
| SCHEMBL23181690 | 0.84 | CYP3A4 (0.39) | CYP3A4FOLH1FAPTTRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730819-B2 | Peptide derivatives having novel linkage structures | BICYCLETX LIMITED (GB) | 2023-08-22 | — | — | US | disclosed |
| US-11696956-B2 | Bicyclic peptide ligands specific for EphA2 | BICYCLETX LIMITED (GB) | 2023-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696956-B2 | Bicyclic peptide ligands specific for EphA2 | EPHA2, EPHB2, ERBB2 | CYP3A4 4184/4885FOLH1 341/4885FAP 1855/4885 |
| US-11730819-B2 | Peptide derivatives having novel linkage structures | DNPEP, LNPEP, ANPEP | CYP3A4 4873/4885FOLH1 349/4885FAP 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.